The oncolytic virus cancer therapy market was valued at USD 17.80 Billion in 2024, driven by rising cancer incidence and increased investment in the development of oncolytic virus therapies across the 8 major markets. The market is expected to grow at a CAGR of 27.10% during the forecast period of 2025-2034, with the values likely to reach USD 195.83 Billion by 2034.
Base Year
Historical Year
Forecast Year
The rising incidence of cancer is generating a strong demand for innovative treatments like oncolytic virus therapies, which is anticipated to contribute to the market growth in the forecast period.
One of the major market trends is the increasing use of oncolytic viruses in combination with other cancer treatments like chemotherapy and radiation.
The presence of a favorable regulatory environment and significant investments in oncolytic virus cancer therapies are some of the factors impacting market value.
Value in USD Billion
2025-2034
Oncolytic Virus Cancer Therapy Market Outlook
*this image is indicative*
Oncolytic viruses refer to a form of immunotherapy where viruses are used to infect and destroy cancer cells. These viruses are genetically modified to selectively infect and replicate within cancer cells, which minimizes the damage to healthy cells. The market for oncolytic virus cancer therapy is driven by the rising incidence of cancer and growing awareness among patients and healthcare providers about this treatment option. The increasing investment in the development of oncolytic virus therapies from both public and private sectors is also supporting the market growth. Further, the growing emphasis on the development of next-generation oncolytic viruses and rising preference for combination therapies is likely to impact the market dynamics.
Rising Incidence of Cancer to Drive the Market Growth
According to the National Cancer Institute, around 2,002,140 new cases of cancer are estimated to be diagnosed in the United States in 2024. Moreover, about 611,720 individuals are projected to die from the disease. Further, it is estimated that 14,910 children and adolescents between the ages of 0 to 19 will be diagnosed with cancer in the country in 2024, with nearly 1,590 of them predicted to die from the disease. Thus, the rise in cancer cases is generating a strong demand for innovative treatments like oncolytic virus therapies, which is anticipated to contribute to the market growth.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Market Breakup by Virus Type
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
The Virus Type Segment Holds a Substantial Market Share
Based on the virus type, the market is segmented into genetically engineered oncolytic viruses including adenovirus, and vaccinia virus, among others, and oncolytic wild-type viruses which comprise reovirus, Newcastle disease virus, vesicular stomatitis virus, and others. The genetically engineered oncolytic viruses segment covers a significant market share as these viruses can be modified to improve their ability to target cancer cells and minimize damage to healthy cells. This customization and increased selectivity of the oncolytic viruses that are genetically engineered allows for better efficacy and safety, thereby contributing to market growth.
Oncolytic Virus Cancer Therapy Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market for oncolytic virus cancer therapy, owing to a significant focus on cancer research and substantial public and private investment in oncolytic virus therapies. The presence of major market players and research institutions actively involved in the development and clinical trials of oncolytic virus therapies further supports the market growth in the region. Moreover, the advanced healthcare infrastructure and high prevalence rate of cancer in the country are poised to fuel the market expansion.
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Theriva Biologics (formerly Synthetic Biologics, Inc.), headquartered in Maryland, United States, is a clinical-stage immuno-oncology company specializing in the development of oncolytic viruses that can overcome the protective barrier present around solid tumors and specifically target tumor cells. One of Theriva’s lead candidates includes an oncolytic adenovirus VCN-1 which is designed to aggressively and selectively replication within tumor cells.
Oncolytic immunotherapy startup company TILT Biotherapeutics Oy is one of the key players in the market known for developing intravenous next-generation oncolytic immunotherapies. The company’s patented TILT® technology, which is based on oncolytic viral therapies, is designed to modify the tumor microenvironment and destroy its ability to affect immune responses.
Boehringer Ingelheim International GmbH, headquartered in Ingelheim am Rhein, Germany, is a global pharmaceutical company. It is involved in the development of innovative cancer treatments including oncolytic virus therapies. The company is also focused on exploring oncolytic viruses in combination with other immuno-oncology agents.
Sweden-based Recipharm AB is a leading pharmaceutical contract development and manufacturing organization known for offering services in the production and development of biologics, including oncolytic viruses. The company invests heavily in facilities and technologies, boasting production facilities in the United Kingdom, France, Germany, Italy, India, and other key regions along with development sites in Israel, the United States, and Sweden.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include ONCOVITA, ViraTherapeutics GmbH, Amgen Inc., and Biotherapy International.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Virus Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share